![](/wp-content/uploads/2018/10/UPE6FrKSRw5sXjE8hu6g.png)
$599
ViaCyte and CRISPR Therapeutics Collaborate for T1DM Stem Cell Therapy
ViaCyte and CRISPR Therapeutics announced a strategic collaboration to modify ViaCyte’s stem cell-based therapy to reduce or eliminate the need for immunosuppression. Below, FENIX provides insight on the collaboration including context from the CRISPR patent dispute.